摘要
多发性骨髓瘤的治疗策略已由传统化疗跨越到靶向免疫治疗。虽然单克隆抗体改善了患者的生存质量,但随着疾病的进展,不少患者会出现不同程度的耐药甚至疾病复发。近年来,新兴的免疫治疗方法(免疫检查点抑制剂、抗体药物偶联物、嵌合抗原受体T细胞免疫治疗等)在此类患者中取得了可观的效果。新型药物及治疗方式与传统治疗方式的搭配组合为临床治疗多发性骨髓瘤提供了新的思路,本研究主要对多发性骨髓瘤新型免疫治疗的现状进行综述,旨在为不同患者的个体化治疗提供参考。
The treatment strategy for multiple myeloma has crossed from traditional chemotherapy to targeted immunotherapy.Although monoclonal antibodies improve the quality of life of patients,as the disease progresses,many patients will develop drug resistance to varying degrees or even disease recurrence.In recent years,emerging immunotherapy approaches(immune checkpoint inhibitor,antibody-drug conjugate,chimeric antigen receptor T cell immunotherapy,etc.)have achieved considerable results in such patients.The combination of new drugs and treatment methods with traditional treatment methods provides a new idea for clinical treatment of multiple myeloma.This study mainly reviews the current situation of new immunotherapy for multiple myeloma,aiming to provide reference for individualized treatment of different patients.
作者
谢芳
刘佳
张连生
李莉娟
Xie Fang;Liu Jia;Zhang Lian-sheng;Li Li-juan(The Second School of Clinical Medicine,Lanzhou University,Lanzhou 730030,China;Department of Hematology,The Second Hospital of Lanzhou University,Lanzhou 730030,China)
出处
《兰州大学学报（医学版）》
2022年第12期79-84,共6页
Journal of Lanzhou University（Medical Sciences）
基金
国家血液系统疾病临床医学研究中心委托课题资助项目(2021WWA01)
兰州市人才创新创业资助项目(2020-RC-48)
兰州大学第二医院萃英科技创新资助项目(CY2017-ZD04,CY2019-MS14)。
